The effect of maternally transferred monoclonal antibody (MAb) on the offspring antibody response to rgp120s F2 was examined in a murine model. Two MAbs were studied: MAb 83.1, which recognizes a determinant in the V3 loop of gp120 from human immunodeficiency virus-I (HIV-1) SF2, and MAb 26.2D3, which recognizes a conserved N-terminal region of gp120 from HIV-1SF2 Offspring were immunized at 18-21 days of age with 100 µg of rgp120SF2 in complete Freund's adjuvant. Offspring immunized in the presence of preexisting MAb 83.1 but not MAb 26.2D3 demonstrated inhibition of the IgG anti-V3 response. The total IgG anti-rgp120SF2 response was not affected by preexisting MAb. Since newborns at risk for HIV may be immunized in the presence of maternal or administered anti-HIV antibody, alternative strategies may be required to circumvent inhibition of the infant's epitope-specific response to HIV immunization by preexisting antibody.
Journal Article Inhibition of the Offspring Anti-Recombinant gp120 Antibody Response to a Human Immunodeficiency Virus Vaccine by Maternal Immunization in a Murine Model Get access Marie T. Jelonek, Marie T. Jelonek Search for other works by this author on: Oxford Academic PubMed Google Scholar Jennifer L. Maskrey, Jennifer L. Maskrey Search for other works by this author on: Oxford Academic PubMed Google Scholar Kathelyn S. Steimer, Kathelyn S. Steimer Search for other works by this author on: Oxford Academic PubMed Google Scholar Barbara J. Potts, Barbara J. Potts Search for other works by this author on: Oxford Academic PubMed Google Scholar Keith W. Higgins, Keith W. Higgins Search for other works by this author on: Oxford Academic PubMed Google Scholar Margaret A. Keller Margaret A. Keller Reprints or correspondence: Dr. Margaret A. Keller, Harbor-UCLA Medical Center, Dept. of Pediatrics, Box 468, 1000 W. Carson St., Bldg. J4, P.O. Box 2910, Torrance, CA. 90509-2910. Search for other works by this author on: Oxford Academic PubMed Google Scholar The Journal of Infectious Diseases, Volume 172, Issue 2, August 1995, Pages 539–542, https://doi.org/10.1093/infdis/172.2.539 Published: 01 August 1995 Article history Received: 27 December 1994 Revision received: 06 March 1995 Published: 01 August 1995
The murine model was developed to assess the effects of maternally transferred HIV hyperimmune globulin or human intravenous immune globulin on the immunization of the offspring at 18–21 days of age with rgp120 SF2 ‐complete Freunds adjuvant. Either HIV hyperimmune globulin or intravenous immune globulin was administered intraperitoneally to post‐partum BALB/c mice and was transferred via milk to the offspring. Both HIV hyperimmune globulin and intravenous immune globulin inhibited the offspring anti‐rgp120 SF2 IgG response to the vaccine. The HIV hyperimmune globulin inhibition persisted for 28 days after immunization while the intravenous immune globulin inhibition was still present at 63 days after immunization. In addition, the intravenous immune globulin had a more generalized immunosuppressive effect, inhibiting the IgG response to both rpg120 SF2 and an additional protein antigen, hen egg‐white lysozyme. Effects of maternal or exogenously administered pre‐existing antibody, including control antibodies (intravenous immune globulin), on the newborn response to HIV and other vaccines must be carefully evaluated when vaccine studies proceed in newborns.
